Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
40.88
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Jun 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
57
58
Next >
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol-Myers Squibb Unusual Options Activity
November 27, 2023
Via
Benzinga
Exploring NYSE:BMY's dividend characteristics.
November 22, 2023
Why BRISTOL-MYERS SQUIBB CO (NYSE:BMY) qualifies as a good dividend investing stock.
Via
Chartmill
Looking Into Bristol-Myers Squibb's Recent Short Interest
November 21, 2023
Via
Benzinga
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
December 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
December 10, 2023
Regulators are already on the case, and their findings will have financial impacts.
Via
The Motley Fool
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
December 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
3 Dividend Stocks Trading at 52-Week Lows
December 09, 2023
All three of these companies have seen brighter days.
Via
The Motley Fool
Insiders Buying Bristol-Myers Squibb And 3 Other Stocks
December 08, 2023
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
Why Bristol Myers Squibb's Shares Are Gaining Today?
December 07, 2023
Bristol Myers Squibb & Co (NYSE: BMY) released topline data from Phase 3 CheckMate -8HW trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to the investigator’s choice of chemotherapy as a...
Via
Benzinga
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers
December 07, 2023
The White House is endorsing a contentious power that permits the government to reclaim patents for specific
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
December 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
December 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend Increase
December 06, 2023
From
Bristol Myers Squibb
Via
Business Wire
2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains
December 06, 2023
Investors hunt for new opportunities in stocks that have been discounted & now present promising options for recovery.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Dirt-Cheap Stocks That Could Skyrocket
December 05, 2023
Low valuations don't always guarantee gains are in the offing. You need a company firing on all cylinders, too.
Via
The Motley Fool
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
December 05, 2023
From
Bristol Myers Squibb
Via
Business Wire
Can Bristol Myers Squibb Keep Its Streak Alive?
November 29, 2023
Bristol Myers Squibb is a $100 billion market cap pharmaceutical company that has raised its dividend every year since 2010 and has paid one since 1933.
Via
Talk Markets
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
November 29, 2023
Tuesday, the FDA said it received reports of patients developing T-cell malig
Via
Benzinga
Exposures
Product Safety
3 stocking stuffers you can buy for yourself
November 29, 2023
These low-beta, deep-value high-yielding stocks are perfect stocking stuffers, even if you buy them for yourself. Rebound is expected in 2024.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
J&J, Gilead, BMS: A look at undervalued dividend payers
November 29, 2023
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown
Via
MarketBeat
Why Is Avidity Biosciences (RNA) Stock Up 15% Today?
November 28, 2023
RNA stock is jumping over 15% in early trading after Avidity announced its expanded alliance with Bristol-Myers Squibb.
Via
InvestorPlace
Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?
November 28, 2023
Avidity Biosciences Inc (NASDAQ: RNA) announced a global licensing and research collaboration with Bristol Myers Squibb & Co (NYSE: BMY) focused on discovering, developing, and commercializing multiple...
Via
Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
November 27, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
3 Resilient Stocks with Massive Potential to Boost Your Wealth
November 26, 2023
These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life.
Via
InvestorPlace
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale
November 24, 2023
Sometimes the stock market offers its own version of Black Friday deals.
Via
The Motley Fool
$1M Bet On Iridium Communications? Check Out These 3 Stocks Insiders Are Buying
November 22, 2023
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
57
58
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.